Big questions hang over Sarepta Duchenne therapy already on market

Big questions hang over Sarepta Duchenne therapy already on market

STAT Plus: As Sarepta awaits approval of new Duchenne drug, big questions hang over therapy already on market

By ADAM FEUERSTEIN

KRISTOFFER TRIPPLAAR/SIPA VIA AP

As the company awaits FDA approval on a new Duchenne drug, the biotech is behind schedule confirming the benefits of its existing medicine.

READ MORE